Kimberly-Clark’s $48.7 Billion Kenvue Deal Faces European شرط
Key Facts
The European Commission approved Kimberly-Clark’s acquisition of Kenvue on October 13, subject to requirements that the company sell feminine-care brands in the European Economic Area. The approval is a regulatory step in a deal the companies announced in November 2025 at an enterprise value of about $48.7 billion. Kimberly-Clark said that value was calculated using its closing share price on October 31, 2025. The European approval does not mean the deal has closed or that all necessary approvals and conditions have been met. The companies plan to complete it in the fourth quarter of 2026, subject to foreign approvals and customary closing conditions.
Kimberly-Clark pledged to sell all its tampon and feminine-care brands in the European Economic Area to address competition concerns. The brands concerned include Kotex, Camelia and Recond, Reuters reported. The pledge adds an implementation step to the deal before completion, as the brands must be transferred within the relevant region. The announced consideration for Kenvue shareholders combines $3.50 in cash and 0.14625 of a Kimberly-Clark share for each share they own at closing. The companies valued the total consideration at about $21.01 per share when they announced the deal, based on the October 31, 2025 price.
Kimberly-Clark’s announced estimates indicate the combined company would generate about $32 billion in annual revenue and about $7 billion in adjusted earnings before interest, taxes, depreciation and amortization, based on 2025 forecasts at the time of the announcement. According to an Associated Press estimate, Kimberly-Clark shareholders would own about 54% of the combined company, compared with about 46% for Kenvue shareholders. The deal would bring together Kenvue’s consumer business with Kimberly-Clark’s healthcare and personal-care operations. But the combined company will not begin operating until closing conditions, including required regulatory approvals, are met. In an exchange offer related to the acquisition, Kimberly-Clark reaffirmed its target of completing the deal in the fourth quarter of 2026.
Kenvue’s second-quarter 2026 results showed net sales rising to $3.955 billion from $3.839 billion in the same period a year earlier, an annual increase of 3.0%. Organic sales grew 1.6%, comprising a 0.9% contribution from price realization and 0.7% from volume growth. Diluted earnings per share rose to $0.24 from $0.22 a year earlier, while adjusted diluted earnings per share increased to $0.31 from $0.29. The chief executive said the company had delivered its third consecutive quarter of growth in net and organic sales. The executive added that first-half 2026 results met or exceeded the company’s expectations across key metrics.
Kenvue said it would not provide forward guidance because of the pending deal with Kimberly-Clark. Lawsuits related to acetaminophen, the active ingredient in Tylenol, remain among the legal risks facing the company. In a statement on an appeals court decision, Kenvue described the ruling as procedural and said it “does not change the fact that the independent and reliable scientific evidence does not establish a link.” The company said the decision does not determine whether there is a general causal relationship between acetaminophen and autism or attention-deficit/hyperactivity disorder. Its annual filing had said it could not at that stage estimate the likelihood or magnitude of potential liability.
Market reaction when the deal was announced on November 3, 2025, was mixed: Kimberly-Clark shares fell 14.6% at the close, while Kenvue shares rose 12.3%. An analyst at Annex Wealth Management said the decline in Kimberly-Clark’s market value exceeded the increase in Kenvue’s value, adding that “the market is expressing its doubts” about the deal. Reuters reported that the offer included a 46% premium for Kenvue shareholders compared with the share price before the announcement. At the close on October 22, 2026, Kimberly-Clark shares stood at $112.32 and Kenvue shares at $19.88. These prices provide a more recent snapshot of the two stocks, while the outcome of the European divestiture requirement and the closing date remain upcoming milestones for the deal.